Intellectual Property Rights and the Public Good

Courtesy of Dr. Ronald Phillips, U. of MinnesotaThe granting of intellectual property rights is intended to stimulate innovation. The twin goals of encouraging innovation and promoting access to inventions require a balancing act between the scope of protection and limits on proprietary rights. In the United States and elsewhere, the government subsidizes research extensively.For developing countries, access to new products, particularly drugs and seeds, is often a question of life and death. Th

Written byRonald Phillips
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Courtesy of Dr. Ronald Phillips, U. of Minnesota

The granting of intellectual property rights is intended to stimulate innovation. The twin goals of encouraging innovation and promoting access to inventions require a balancing act between the scope of protection and limits on proprietary rights. In the United States and elsewhere, the government subsidizes research extensively.

For developing countries, access to new products, particularly drugs and seeds, is often a question of life and death. The market power inherent in intellectual property may restrict access by poorer consumers. Furthermore, coordination problems and the transaction costs involved in negotiating terms of access to patented innovations invariably raise the cost of producing and distributing inventions in developing nations.

One example is "golden rice," which is enhanced for beta carotene (provitamin A). It provides hope for alleviating the severe vitamin A deficiency that causes blindness in a half-million children every year. Extensive patenting has ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies